Kymera Therapeutics

Advancing the field of targeted protein degradation to deliver breakthrough medicines for previously untreatable diseases

[Kymera Therapeutics @KymeraTx]

In the latest edition of the New Paradigms newsletter, Kymera founders @NelloMainolfi and @LifeSciVC reflect on the founding thesis behind Kymera and the early decisions that helped shape the company we are today. Watch the full conversation to hear how those ideas continue to inform the path ahead!

[Nello Mainolfi @NelloMainolfi]

It was great to sit down with @KymeraTx co-founder @LifeSciVC and revisit our early days, from the science that brought us together to the early decisions that still shape how we are building the company today. Ten years later, I’m proud of how far we’ve come and even more focused on what lies ahead as we continue working to deliver a new generation of medicines to patients around the world.

https://t.co/jAVRkB5ZLi

[Kymera Therapeutics @KymeraTx]

Today we shared our second quarter 2026 financial results and highlighted recent company updates and upcoming milestones.

Discover how we’re advancing an industry leading pipeline of oral small molecule degrader medicines in immunology with the potential to transform patients’ lives around the world: https://t.co/NPznMiAzUI

#RevolutionizingImmunology $KYMR

[Kymera Therapeutics @KymeraTx]

$KYMR Join us on August 5th for our quarterly financial results and latest company updates: https://t.co/fjvcNDEVWW

[Kymera Therapeutics @KymeraTx]

Today, we announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Terence brings deep immunology drug development experience to Kymera as we advance our oral immunology portfolio and work to expand treatment options for patients living with immuno-inflammatory diseases. Welcome to the team, Terence!

Read more: https://t.co/jYnVoe1s9t

[Kymera Therapeutics @KymeraTx]

This morning, our CEO, @NelloMainolfi, will join fellow biopharma leaders at the @BiotechTV U.S. Science Summit to discuss the state of innovation and how bold ideas and a shared commitment to impact can advance drug discovery and shape the future of healthcare.

Follow along on @BiotechTV's channels for event highlights!

[Kymera Therapeutics @KymeraTx]

Thrilled to be at the @AADskin Innovation Academy this week, connecting with the dermatology community and discussing novel approaches with the potential to shape the future of patient care.

Stop by our poster presentation to learn more about KT-621, our investigational, first-in-class, oral STAT6 degrader.

#RevolutionizingImmunology #AADInnovation2026

[Kymera Therapeutics @KymeraTx]

Our Founder, President & CEO @NelloMainolfi joined @CNBCFastMoney to discuss the momentum behind KT-621, our vision for advancing a new generation of oral medicines, and how we're working to transform treatment for patients living with chronic inflammatory diseases. Watch the full interview: https://t.co/k2hKTqHlEA

#RevolutionizingImmunology $KYMR

[CNBC's Fast Money @CNBCFastMoney]

$KYMR shares notching a record close after giving a better-than-expected timeline for its fast-tracked ezcema oral treatment trial.

@KymeraTx CEO on record stock run, upbeat eczema oral treatment trial data

https://t.co/ENc6LiRnco

[Kymera Therapeutics @KymeraTx]

Today, we announced the appointment of Elizabeth Laws as Senior Vice President, KT-621 Development Program Leader. Liz brings extensive experience across immunology clinical development, global franchise strategy and commercialization to Kymera as we continue advancing KT-621, our investigational, first-in-class, oral STAT6 degrader, as a potential paradigm-shifting oral therapy for multiple Type 2 inflammatory diseases. Welcome to the team, Liz! https://t.co/6Qh1zpFkq2

#RevolutionizingImmunology

[BiotechTV @BiotechTV]

𝐒𝐩𝐞𝐚𝐤𝐞𝐫 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: At our upcoming summit, we will highlight science happening today that has the potential to change medicine. We're excited to welcome @KymeraTx's @NelloMainolfi, a pioneer in protein degraders, as a speaker.

More: https://t.co/yYA1FWmxMw

[Kymera Therapeutics @KymeraTx]

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines.

This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases.

Read more in our press release: https://t.co/W3Mgi3SQZr

[Kymera Therapeutics @KymeraTx]

We’re proud to join the @AllergyAsthmaHQ Corporate Council and support AAN’s important work advancing patient-centered research, education, advocacy, and access to care for people living with asthma, allergies, and related conditions.

We look forward to partnering with the AAN team and their community to help improve the lives of patients and their families.

[Allergy & Asthma Network @AllergyAsthmaHQ]

We are excited to welcome @KymeraTx to the Allergy & Asthma Network Corporate Council!

Corporate partnerships play a vital role in accelerating patient‑focused solutions, shaping more inclusive clinical research, and advancing our mission to improve the lives of people with asthma, allergies, and related conditions.

We’re proud to begin this collaboration with Kymera Therapeutics.

Explore our Corporate Council: https://t.co/z3QPet4QXf

[Kymera Therapeutics @KymeraTx]

We’re looking forward to an impactful few days in Nashville at the Revolutionizing Atopic Dermatitis conference, where the dermatology community will come together to discuss unmet patient needs and emerging therapeutic approaches in atopic dermatitis. Stop by our exhibition table and poster presentation on KT-621, our investigational, first-in-class, oral STAT6 degrader, to learn more!

#RAD2026 #RevolutionizingImmunology

[Kymera Therapeutics @KymeraTx]

At the Japanese Dermatological Association Annual Meeting, we presented Phase 1 data in healthy Japanese adults for KT-621, our investigational, first-in-class, oral STAT6 degrader.

The presentation highlights KT-621’s compelling profile and its potential to transform treatment paradigms for patients living with chronic Type 2 inflammatory conditions.

Learn more in our latest press release: https://t.co/lZwNbPGfG1
#RevolutionizingImmunology

[Kymera Therapeutics @KymeraTx]

Today, we announced that the first participant has been dosed in the Phase 1 clinical trial of KT-485, our oral, potent and selective IRAK4 degrader being advanced by @sanofi under our collaboration.

This milestone marks an important step forward for KT-485 and its potential to offer a novel oral approach to addressing a key pathway involved in several immuno-inflammatory conditions. Read the full press release: https://t.co/c4uougEV1z

#RevolutionizingImmunology

[Kymera Therapeutics @KymeraTx]

We’re thrilled to announce the appointment of Penny Carlson as our Senior Vice President, Development Operations. She brings more than two decades of leadership across global clinical program management, study execution and data management to Kymera as we advance our industry-leading oral immunology pipeline. Welcome to the team, Penny! https://t.co/9z889iGC9F

[Kymera Therapeutics @KymeraTx]

Today, we announced new preclinical lupus data for KT-579, our first-in-class, oral IRF5 degrader, at the @eular_org and @FOCISimmunology congresses.

IRF5 is a historically undrugged target that unlocks key biological pathways implicated in complex autoimmune diseases. The data shared highlight KT-579’s compelling preclinical profile and its potential to offer a novel oral therapy.

Learn more: https://t.co/ZAYcMZTGmJ
#RevolutionizingImmunology

[Kymera Therapeutics @KymeraTx]

$KYMR Happening soon! Tune in to our fireside chat this morning at the @Jefferies Global Healthcare Conference where our CEO, @NelloMainolfi, will discuss our novel approach in immunology and upcoming milestones across our industry-leading pipeline of oral degrader medicines. Live webcast here: https://t.co/Y6FCN50J4J

[Kymera Therapeutics @KymeraTx]

$KYMR Don’t miss our fireside chat at the @Jefferies Global Healthcare Conference next week! Learn more: https://t.co/HlqJk1T3Pr

[Kymera Therapeutics @KymeraTx]

$KYMR Don’t miss our fireside chat this morning at the @RBC Global Healthcare Conference where our team will discuss progress and upcoming milestones across our industry-leading pipeline of oral immunology programs. Listen to the live webcast here: https://t.co/m8CiLUmnf4

[Kymera Therapeutics @KymeraTx]

We’re excited to announce oral presentations at the @SocInvestDerm Annual Meeting and @atscommunity Respiratory Innovation Summit featuring KT-621, our investigational, first-in-class, oral STAT6 degrader.

We look forward to engaging with the dermatology and respiratory communities and sharing our vision for advancing a novel oral medicine with the potential to transform treatment paradigms for millions of patients living with Type 2 inflammatory diseases.

Learn more in our latest press release: https://t.co/tCVTs2vufm

#RevolutionizingImmunology #SID2026 #ATS2026 #RIS2026 #Dermatology #Respiratory